Heterogeneity in Producer's Marketing Strategy

Producers can make their market timing decisions either based on fundamental or technical analysis to reach specific financial target. A generalized mixture model is used to discriminate producers into more than one segment according to their marketing strategies. The heterogeneous selling response is the same within each segment.Marketing,

Differential stiffness effects

Differential stiffness as developed in NASTRAN is a linear change in stiffness caused by applied loads. Examples of differential stiffness are the stiffening effects of gravity forces in a pendulum, centrifugal forces in rotor blades and pressure loading of shell structures. In cases wherein this stiffness caused by a load is destabilizing, the differential stiffness concept lends itself to nonlinear structural analysis. Rigid Formats 4 (static analysis with differential stiffness) and 13 (normal modes with differential stiffness) are specifically designed to account for such stiffness changes. How pressure loading may be treated in these rigid formats is clarified. This clarification results from modal correlation of Ground Vibration Test (GVT) results from the empty and pressurized Filament Wound Case (FWC) quarter-scale Space Shuttle solid rocket booster (QSSRB). A sketch of the QSSRB cantilevered to the floor by its external tank attachments is shown

Blind channel identification based on second-order statistics: a frequency-domain approach

In this communication, necessary and sufficient conditions are presented for the unique blind identification of possibly nonminimum phase channels driven by cyclostationary processes. Using a frequency domain formulation, it is first shown that a channel can be identified by the second-order statistics of the observation if and only if the channel transfer function does not have special uniformly spaced zeros. This condition leads to several necessary and sufficient conditions on the observation spectra and the channel impulse response. Based on the frequency-domain formulation, a new identification algorithm is proposed

Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study

BACKGROUND: Only a few patients with pancreatic ductal adenocarcinoma (PDAC) recurring after curative resection and peri-operative (neoadjuvant and adjuvant) therapy are included in clinical trials of metastatic PDAC. As such, there is a paucity of data to guide treatment after relapse, and patients are treated similarly to those with de novo metastatic PDAC (mPDAC). We evaluated the patterns of chemotherapy use and over-all survival (OS) in patients with recurrent PDAC (rPDAC) following curative therapy. METHODS: In this retrospective study, the Indiana University pancreatic cancer database was used to identify patients with PDAC who underwent curative resection and subsequently developed recurrence. Demographics, tumor and treatment characteristics were collected. Patients were broadly divided into those who received chemotherapy for rPDAC and those who did not. Patients in the former category were further subdivided into those who received single agent therapy, any standard combination therapy (5-fluorouracil/irinotecan/oxaliplatin combination or gemcitabine/nab-paclitaxel) and those who received non-standard combinations. Survival analysis was performed by the Kaplan-Meier method. Log rank tests were used to determine differences in survival between treated rPDAC patients and those not treated. Cox regression analysis was employed to evaluate factors associated with OS. RESULTS: We identified 435 patients with resected PDAC treated between 2008 and 2014. Two hundred and twenty-three patients (51.2%) were diagnosed with rPDAC. Of these, 140 patients (63%) received chemotherapy whereas 71 patients (32%) did not receive chemotherapy. The 74 patients (53%) who received any standard, approved multiagent combination regimen had a median OS of 14 months compared to 8 months for the 47 patents (34%) who received other non-standard combinations and the 19 (13%) who received single agent therapy (P = 0.029). Multivariate cox regression analysis showed that margin negative resection, peri-operative therapy, radiotherapy and the use of any chemotherapy for rPDAC were associated with improved OS. CONCLUSION: Our findings support the use of standard approved multi-agent therapy in rPDAC. Patients derive significant benefit from these standard combination therapies with median OS that is comparable to what is observed with treatment for de novo mPDAC